ATTD 2022: Mic Drop Moment As Medtronic Presents 780G Data Proving Closed Loop Ability
Executive Summary
Results of the ADAPT study presented at the Advanced Technologies & Treatments for Diabetes conference in Barcelona support Medtronic’s hope that the 780g insulin pump will help to turn around its diabetes business or make it an attractive acquisition for another company.
You may also be interested in...
Minute Insight: Real-World Data Supports Medtronic’s 780G Insulin Pump
Postmarket data from Europe and Chile, announced at the American Diabetes Association conference, offer more support for Medtronic’s faith in its MiniMed 780G system with the Guardian 4 sensor.
Medtronic Starts Planned Portfolio Simplification With DaVita Renal Care Spin Off
The new independent kidney-care company will be equally co-owned by both companies. It will include all of Medtronic’s renal care solutions business, including renal access, acute therapies, and chronic therapies.
Medtronic Reviews Its Portfolio, Driving Speculation It May Sell Diabetes Unit
During its recent quarterly earnings call, Medtronic CEO Geoff Martha reiterated that the company expects to announce changes over the next year that will help it drive growth and shareholder value. Analysts suspect Medtronic’s struggling diabetes business is probably the top candidate for a sale.